Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

LY96 anticorps

LY96 Reactivité: Humain FACS, InhA Hôte: Souris Monoclonal 18H10 unconjugated
N° du produit ABIN2192085
  • Antigène Voir toutes LY96 Anticorps
    LY96 (Lymphocyte Antigen 96 (LY96))
    Reactivité
    • 50
    • 12
    • 5
    • 2
    • 1
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 41
    • 13
    Souris
    Clonalité
    • 44
    • 10
    Monoclonal
    Conjugué
    • 27
    • 9
    • 5
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp LY96 est non-conjugé
    Application
    • 40
    • 22
    • 8
    • 7
    • 6
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Inhibition Assay (InhA)
    Stérilité
    0.2 μm filtered
    Immunogène
    TLR4/MD-2 expressing CHO cells/ chimeric TLR4/MD-2 fusion protein
    Clone
    18H10
    Top Product
    Discover our top product LY96 Anticorps primaire
  • Indications d'application
    For flow cytometry, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, dilutions have to be made according to the amounts of MD-2 to be inactivated.
    Restrictions
    For Research Use only
  • Buffer
    PBS, containing 0.1 % bovine serum albumin.
    Stock
    4 °C
    Stockage commentaire
    Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
    Date de péremption
    12 months
  • Tissières, Dunn-Siegrist, Schäppi, Elson, Comte, Nobre, Pugin: "Soluble MD-2 is an acute-phase protein and an opsonin for Gram-negative bacteria." dans: Blood, Vol. 111, Issue 4, pp. 2122-31, (2008) (PubMed).

    Daubeuf, Mathison, Spiller, Hugues, Herren, Ferlin, Kosco-Vilbois, Wagner, Kirschning, Ulevitch, Elson: "TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 179, Issue 9, pp. 6107-14, (2007) (PubMed).

    Elson, Dunn-Siegrist, Daubeuf, Pugin: "Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria." dans: Blood, Vol. 109, Issue 4, pp. 1574-83, (2007) (PubMed).

    Pugin, Stern-Voeffray, Daubeuf, Matthay, Elson, Dunn-Siegrist: "Soluble MD-2 activity in plasma from patients with severe sepsis and septic shock." dans: Blood, Vol. 104, Issue 13, pp. 4071-9, (2004) (PubMed).

  • Antigène
    LY96 (Lymphocyte Antigen 96 (LY96))
    Autre désignation
    Md-2 (LY96 Produits)
    Synonymes
    anticorps MD2, anticorps ESOP-1, anticorps MD-2, anticorps ly-96, anticorps Ly-96, anticorps Md2, anticorps lymphocyte antigen 96, anticorps LY96, anticorps Ly96
    Sujet
    The monoclonal antibody 18H10 reacts with MD-2, an accessory molecule of the Toll-like receptor 4 (TLR4, CD284). TLRs belong to a family of proteins that specifically recognizes and senses microbial products. They are highly conserved throughout evolution and act as innate immune recognition receptors against many pathogens. TLR4 is a functional receptor for gram-negative bacterial lipopolysaccharides (LPS). TLR4 associates with MD-2 which is absolutely required for LPS-induced activation of TLR4. MD-2 exists as a cell surface protein in association with TLR4. It also exists as secreted forms consisting of MD-2 monomers and multimers (sMD-2). Circulating sMD-2 is mainly present as a doublet of ~20 and 25 kD, representing differentially glycosylated forms. Unlike TLR4, sMD-2 binds directly LPS without the need of soluble CD14 (sCD14). However, LPS-MD-2 interactions are increased when LPS is pretreated with CD14. Only monomeric sMD-2 is biologically active and able to associate with TLR4 and LPS. sMD-2 circulates in plasma of healthy individuals as a non-active, polymeric protein. In septic plasma, the total amount of sMD-2 was strongly elevated and contained both sMD-2 polymers and monomers. Soluble MD-2 is proposed to be an important mediator of organ inflammation during sepsis. During experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. This parallels enhanced TLR4 costimulatory activity. In vitro studies revealed that sMD-2 release appears to be restricted to endothelial and dendritic cells. The monoclonal antibody 18H10 reacts with MD-2. However, it does not react with sMD-2. In addition, the monoclonal antibody 18H10 is able to inhibit bacterial binding to MD-2. Aliases Lymphocyte antigen 96, ESOP-1, LY96
    Pathways
    Signalisation TLR, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Toll-Like Receptors Cascades
Vous êtes ici:
Support technique